As a new type of foreign trade service provider driven by dual engines of technology transformation and export services, HiSiaddi has established a "1+2+3+4=1" service system, offering access to original factory supplies from multiple well-known brands of Probiotics.
Adopting the "1+1>2" business model, HiSiaddi focuses on the integrated development of technology transformation and export business, and consistently tracks the global Probiotics market from both scientific research and market perspectives. Today, we will analyze the new shifts and trends of the global Probiotics market from a professional standpoint.
If you need more comprehensive and valuable information on the Probiotics market, please contact HiSiaddi customer service.
· Bacillus Coagulans: Boasting three core advantages—high temperature resistance (survives 80-90°C processing), gastric acid tolerance, and long shelf life (24 months at ambient temperature), it has become the absolute leader in the thermotolerant probiotics track. Its market size will reach USD 1.855 billion in 2026, with a CAGR of 6.8% from 2026 to 2033, accounting for 46.8% of the thermotolerant probiotics market share. Unlike traditional lactic acid bacteria (which require cold chain and have short shelf lives), it can be directly added to baked foods, hot beverages, and high-temperature sterilized feeds, breaking restrictions in processing, storage and transportation scenarios.
· Clostridium Butyricum: Focused on core functions including intestinal mucosal repair, anti-inflammation and immune regulation, it recorded a global market size of USD 1.782 billion in 2025, with a CAGR of 8.6% from 2025 to 2032—faster growth than Bacillus Coagulans. Its core trend lies in medicalization and precision: it is expanding from ordinary feed additives and health food raw materials to functional pharmaceutical intermediates, post-operative intestinal repair preparations, and auxiliary therapeutic raw materials for Inflammatory Bowel Disease (IBD), with clinical evidence as the core competitiveness.
1.
Feed Industry (Largest Rigid-Demand Market) Global "antibiotic ban and restriction" policies have been fully implemented (EU fully bans growth-promoting antibiotics in 2026, China enforces mandatory antibiotic-free breeding, and Southeast Asian countries follow suit). The two strains are core alternatives to antibiotics, triggering explosive demand.
2.
o Bacillus Coagulans: Focuses on livestock and poultry intestinal health, diarrhea prevention and control, and feed conversion ratio improvement, applicable to all categories of pigs, chickens and aquatic products, accounting for 35% of feed sector consumption in 2026.
o Clostridium Butyricum: Specializes in aquatic products (shrimp, crabs, fish) for intestinal mucosal repair, water quality improvement and anti-stress effects, as well as rumen health of ruminants, with a 12% growth rate in the aquatic sector.
3.
Food & Beverage (High-Growth Potential Market) Consumers have widely accepted the concept that "intestinal health equals systemic health", making ambient-temperature functional foods a booming niche.
4.
o Bacillus Coagulans: Added to baked bread, biscuits, ambient yogurt, plant protein drinks and energy bars, solving the pain point that traditional probiotics cannot withstand high-temperature processing. The CAGR of its food sector application will hit 17.6% in 2026.
o Clostridium Butyricum: Penetrates high-end fermented foods, intestinal functional drinks and probiotic chocolate, differentiated by the selling point of "deep repair and anti-inflammation".
5.
Health Products & Pharmaceuticals (High-Value-Added Market)
6.
o Health Products: Bacillus Coagulans targets daily intestinal conditioning and bidirectional regulation of constipation/diarrhea, available in capsules, powder and gummy forms, accounting for 52% of probiotic raw materials for health products in 2026; Clostridium Butyricum focuses on post-operative recovery, sensitive gut relief and immunity enhancement, targeting middle-aged, elderly and post-surgery populations.
o Pharmaceuticals: Clostridium Butyricum is included in pharmacopoeias of multiple countries (China, Japan, South Korea) for the treatment of antibiotic-associated diarrhea, enteritis and Irritable Bowel Syndrome (IBS). Pharmaceutical-grade raw materials require a purity of ≥99.9%, with prices 3-5 times higher than feed-grade equivalents.
1.
Competition over Strain Activity and Purity The market has shifted from merely meeting viable count standards to pursuing high activity, high stability and high colonization rates. The mainstream specification of Bacillus Coagulans has upgraded from 10 billion CFU/g to 20-50 billion CFU/g, with third-party testing mandatory for gastric acid tolerance, bile tolerance and high-temperature resistance. For Clostridium Butyricum, requirements include anaerobic activity ≥90%, miscellaneous bacteria rate ≤0.1%, and absence of drug-resistant genes; pharmaceutical-grade variants demand whole-genome sequencing reports.
2.
3.
Upgrading Fermentation and Formulation Technologies
4.
o Bacillus Coagulans: Solid-state fermentation + low-temperature spray drying replaces traditional liquid fermentation, cutting costs by 20% and boosting activity by 30%. It can be processed into microcapsule embedded and sustained-release particles to adapt to various end formulations.
o Clostridium Butyricum: Advanced anaerobic submerged fermentation + freeze-drying protection technology addresses the longstanding pain points of low activity and easy deactivation in traditional processes. High-activity freeze-dried bacterial powder will account for 60% of total supply in 2026.
5.
Surge in Customization Demand Purchasers no longer settle for standard products, but demand customized strains, formulas and formulations. Examples include feed clients requiring exclusive strains that withstand 85°C pelleting temperatures and boost growth; food clients requesting odor-free, taste-neutral custom bacterial powder; pharmaceutical clients demanding strains with high colonization rates and well-defined anti-inflammatory targets.
6.
· Unified global trend: Probiotics are reclassified from ordinary food raw materials to functional raw materials or pharmaceuticals, with countries tightening supervision. Strain safety, efficacy and traceability have become core requirements.
· Core certification barriers:
o Bacillus Coagulans: Mandatory FDA GRAS certification, EU QPS certification, inclusion in China’s permitted food strain list, and ISO 22000 food safety certification.
o Clostridium Butyricum: Pharmaceutical-grade variants require pharmacopoeia inclusion, clinical trial reports and GMP certification; feed-grade variants need EU Feedap certification and China’s feed additive filing.
· Standardized labeling and efficacy claims: The EU prohibits disease-treatment promotional language, only permitting functional descriptions such as "maintaining intestinal flora balance and promoting digestion". The US mandates full genome traceability of strains, clear labeling of viable counts, and complete evidence chains to support efficacy claims.
1. Sharply Rising Cost Pressures Driven by antibiotic-free policies, demand has skyrocketed while high-quality strains remain in short supply. Raw material prices for Bacillus Coagulans rose 15% and Clostridium Butyricum 20% from 2025 to 2026, squeezing profit margins of small and medium-sized feed enterprises.
2. Uneven Strain Quality The market is flooded with low-quality raw materials featuring only 50% of the labeled viable counts, excessive miscellaneous bacteria, and positive drug-resistant gene results. These lead to poor breeding outcomes (unreduced diarrhea rates, unimproved feed-to-meat ratios) and complaints from terminal farmers.
3. Insufficient Adaptability Different breeding categories (pigs/chickens/aquatic products) and growth stages (juvenile/adult) impose vastly different requirements on strain heat resistance, colonization rates and efficacy targets. Universal strains deliver weak performance, while customized strains carry high procurement costs.
4. Compliance Risks Multiple countries mandate strain traceability, safety assessment reports and complete production qualifications for feed additives. Small and medium feed enterprises lack compliance review capabilities and face penalties for non-compliant raw materials.
1. Processing Adaptability Challenges High-temperature baking (180-220°C), high-pressure sterilization and acidic environments (pH 3-4) reduce activity of ordinary strains by 50%-80%, resulting in underperforming end products and low consumer repurchase rates.
2. Sensory Interference Issues Some strains carry inherent odors and bitter tastes that compromise food flavor after addition, requiring extra flavor masking agents and increasing formulation costs.
3. Compliance Risks for Labeling and Efficacy Claims Countries have intensified reviews of "probiotics, intestinal health" promotional claims. Unsupported efficacy advertising incurs heavy fines (up to 5% of annual revenue in the EU). Small and medium enterprises lack reserves of clinical data to back up claims.
4. Unstable Supply Chains Food enterprises rely on long-term orders and steady demand, yet limited production capacity for premium strains frequently causes stockouts and delivery delays during peak seasons, disrupting production schedules.
1. Severe Homogenization Competition 90% of health products on the market use generic Bacillus Coagulans or Clostridium Butyricum with undifferentiated efficacy. Price wars have slashed gross profit margins from 50% to 25%.
2. Lack of Clinical Evidence High-end health product markets (Europe, America, Japan, South Korea) demand exclusive human clinical trial reports (minimum 2 trials), well-defined efficacy targets and complete colonization data for strains. Most small and medium enterprises only provide generic strain test reports, barring entry into high-end channels.
3. Insufficient Formulation Adaptation Technology Capsules, powder, gummies, oral liquids and other dosage forms impose distinct requirements on strain embedding technology, stability and solubility. Small and medium enterprises lack formulation expertise, leading to product caking, rapid activity attenuation and poor solubility.
1. Extreme Purity and Activity Requirements Pharmaceutical-grade raw materials demand purity ≥99.9%, viable counts ≥50 billion CFU/g, miscellaneous bacteria rate ≤0.1%, zero pyrogens and zero endotoxins, with production processes complying with GMP standards. Procurement costs are 5-8 times higher than feed-grade equivalents.
2. Long Clinical and Registration Cycles Clostridium Butyricum pharmaceutical formulations require Phase I/II/III clinical trials and drug regulatory approval, a process spanning 3-5 years with investment exceeding RMB 100 million—an unaffordable burden for small and medium enterprises.
3. Strain Patent Barriers Core high-activity, high-colonization strains are monopolized by European, American and Japanese enterprises. Domestic pharmaceutical enterprises either pay patent licensing fees for procurement or face infringement risks.
1. Explosive Rigid Demand for Antibiotic-Free Breeding Global antibiotic-free policies have been fully rolled out, creating an antibiotic replacement market worth over USD 100 billion. As core alternative raw materials, the two strains will sustain growing demand. Enterprises with stable supply chains of premium strains will capture larger market shares.
2. Premium Pricing via Differentiated Products Procuring customized, high-activity strains enables enterprises to launch differentiated antibiotic-free feed products focused on intestinal health and growth promotion. Terminal selling prices can rise by 10%-15%, lifting gross profit margins by 5-8 percentage points.
3. Industrial Chain Integration Opportunities Deepen partnerships with premium strain suppliers and co-develop integrated "strain-feed-breeding" systems to cut raw material costs and boost end-customer stickiness.
1. Blue Ocean Market for Ambient-Temperature Probiotics Traditional probiotics depend on cold chains, limiting applicable scenarios. Thermotolerant Bacillus Coagulans can be incorporated into ambient-temperature foods, representing a market worth over USD 100 billion with a CAGR of 12.8% from 2026 to 2036. Enterprises that deploy early will seize first-mover advantages.
2. Dividends from the Clean Label Trend Consumers prefer "natural, additive-free, functional" foods. The two strains feature natural safety and no side effects, capable of replacing chemical additives and boosting end-product competitiveness.
3. Cross-Border Innovation Opportunities Expand beyond traditional yogurt and health products to new scenarios including baked goods, snacks, hot drinks and plant-based foods to unlock incremental markets. For example, bread fortified with Bacillus Coagulans commands a 20% premium at retail.
1. Surging Segmented Intestinal Health Track The global intestinal health health product market exceeds USD 50 billion, with precise, functional, high-activity products dominating demand. Enterprises with clinical evidence and exclusive strains can penetrate high-end markets with gross profit margins of 60%-80%.
2. Cross-Border E-commerce Dividend Awareness of intestinal health is rising rapidly in emerging markets including Southeast Asia, the Middle East and Latin America, where probiotic health product demand surges and regulatory frameworks are relatively lenient. Small and medium enterprises can quickly expand overseas via cross-border e-commerce to avoid cutthroat competition in European and American red oceans.
3. Formulation Innovation Opportunities Demand surges for convenient dosage forms such as gummies, oral liquids and chewable tablets. Procuring customized strains with strong adaptability, stability and solubility enables differentiated dosage form products targeting young consumer groups.
1. Booming Microecological Therapy for Intestinal Disorders The incidence of Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS) and antibiotic-associated diarrhea rises year by year, with limited conventional treatment options. Clostridium Butyricum microecological preparations deliver remarkable clinical efficacy, creating urgent market demand.
2. Favorable Policy Support Multiple countries encourage R&D of microecological pharmaceuticals. China has included intestinal microecological preparations in the "Major New Drug Creation" special program with R&D subsidies; Europe and America accelerate approval for probiotic pharmaceuticals, rewarding enterprises with independent R&D capabilities.
3. Patent Licensing and Cooperation Opportunities Domestic strain suppliers have advanced independent R&D capabilities, with certain high-activity strains breaking foreign patent monopolies. Pharmaceutical enterprises can reduce procurement costs and avoid infringement risks through patent licensing and joint R&D.
1. Optimize Supply Chains, Lock in Premium Production Capacity and Sign Long-Term Agreements
o Prioritize suppliers with self-owned fermentation bases, independent strain R&D and full-chain quality inspection systems; avoid middleman traders to cut procurement costs by 10%-15%.
o Sign 1-3 year long-term supply agreements to lock prices and production capacity, mitigating peak-season price hikes and stockout risks; define quality compensation clauses with clear liability standards for substandard viable counts and excessive miscellaneous bacteria.
2. Precision Strain Selection, Reject Generic Strains
o Pigs & Poultry: Select Bacillus Coagulans (20 billion CFU/g, resistant to 85°C pelleting) for diarrhea prevention and growth promotion.
o Aquatic Products (Shrimp & Crabs): Select Clostridium Butyricum (30 billion CFU/g, high anaerobic activity) for intestinal repair, anti-stress effects and water quality improvement.
o Juvenile Animals: Adopt microcapsule embedded strains to enhance gastric acid tolerance and lift colonization rates by 40%.
3. Establish Three-Tier Quality Inspection System to Eliminate Substandard Raw Materials
o Pre-Warehousing: Test viable counts, miscellaneous bacteria rate, moisture and drug-resistant genes for every batch, with third-party test reports issued by ISO 17025 accredited laboratories.
o Mid-Production: Inspect activity retention rate post-pelleting (minimum 70%) to avoid excessive processing losses.
o End-Terminal: Track breeding outcomes (diarrhea rate, feed-to-meat ratio, survival rate) and build a supplier scoring system to phase out underperforming vendors.
4. Upgrade Compliance, Complete Qualification Audits and Preempt Certification Layout
o Require suppliers to provide feed additive filings, Feedap certification, safety assessment reports and strain traceability documents.
o Proactively apply for antibiotic-free feed certification and ISO 22000 food safety certification to enhance product credibility and align with farmer demand.
1. Strain Selection Focused on Heat Resistance, Stability and Neutral Odor
o High-Temperature Processing (Baking/Sterilization): Select heat-resistant Bacillus Coagulans (tolerant to 90°C, stable for 24 months at ambient temperature) with activity retention ≥80%.
o Acidic Beverages (pH 3-4): Adopt acid-resistant Bacillus Coagulans or Clostridium Butyricum; embedded variants deliver activity retention ≥70%.
o Flavor-Sensitive Products: Choose odorless, low-bitterness strains to avoid compromising product taste.
2. Upgrade Formulation Technology with Microcapsule Embedding for Enhanced Stability
o Procure microcapsule embedded strains (heat-resistant, acid-resistant, sustained-release) to resolve activity attenuation during processing and storage, delivering ≥90% activity retention for end products over shelf life.
o Collaborate with suppliers to customize embedding technology for solid/liquid dosage forms, reducing flavor masking agent usage and optimizing sensory performance.
3. Standardize Promotional Claims, Reserve Clinical Evidence and Regulate Labeling Language
o Require suppliers to provide exclusive strain efficacy data, safety assessment reports and clinical trial summaries to support compliant claims such as "maintaining intestinal flora balance and promoting digestion".
o Clearly label viable counts, strain codes, shelf life and storage conditions on packaging to avoid false advertising; commission local institutions for compliance audits for European and American markets to eliminate fine risks.
4. Drive Product Innovation, Expand Cross-Border Scenarios and Build Differentiated Value
o Tap new scenarios including baked goods, snacks, hot drinks and plant-based foods, e.g., Bacillus Coagulans fortified bread and Clostridium Butyricum plant milk, commanding a 15%-20% retail premium.
o Launch portable single-serve and ready-to-eat formulations to meet young consumers’ demand for convenience and boost repurchase rates.
1. Upgrade Strains, Prioritize High-Activity, High-Colonization Strains with Exclusive Clinical Data
o Abandon low-cost generic strains; procure high-activity strains (50 billion CFU/g) with high colonization rates (≥30%) to build differentiated selling points centered on "deep repair and precise conditioning".
o Prioritize strains supported by minimum 2 exclusive human clinical trials with well-defined efficacy targets: e.g., Clostridium Butyricum for IBS relief and Bacillus Coagulans for constipation management.
2. Innovate Formulations Focused on Convenience, High Efficacy and Superior Consumer Experience
o Develop convenient dosage forms including gummies, oral liquids and chewable tablets with microcapsule embedding and sustained-release technology to boost absorption efficiency, lifting terminal selling prices by 30%-50%.
o Launch high-concentration, easy-to-swallow capsules for middle-aged and elderly consumers; fruit-flavored gummies and portable powder sachets for younger demographics.
3. Break Into High-End Markets, Reserve Clinical Evidence and Access European, American, Japanese and Korean Channels
o Co-develop joint clinical trials with suppliers to generate human trial data supporting high-end market efficacy claims.
o Secure FDA GRAS, EU QPS and Japan MHLW certifications to access high-end supermarkets, pharmacies and wellness management centers in Europe, America, Japan and South Korea, lifting gross profit margins to 60%-80%.
4. Deploy Emerging Markets, Leverage Cross-Border E-commerce to Capture Incremental Demand in Southeast Asia & the Middle East
o Target emerging markets including Southeast Asia, the Middle East and Latin America via cross-border e-commerce platforms Amazon, Shopee and Lazada to avoid saturated European and American markets.
o Develop cost-effective basic intestinal conditioning products aligned with local consumer preferences to rapidly capture market share and build brand influence.
1. Raw Material Sourcing Focused on Pharmaceutical-Grade, High-Purity, Fully Qualified Strains
o Procure pharmaceutical-grade Clostridium Butyricum (purity ≥99.9%, viable counts ≥50 billion CFU/g, miscellaneous bacteria rate ≤0.1%) manufactured under GMP standards, with pharmacopoeia inclusion, clinical trial reports and strain patents.
o Implement full incoming inspection for raw materials, testing purity, activity, pyrogens, endotoxins and sterility to meet pharmaceutical-grade specifications.
2. Boost R&D Investment, Focus on Microecological Preparations and Accelerate Clinical Trials & Registration
o Develop single-strain and compound Clostridium Butyricum formulations (combined with other probiotics/prebiotics) targeting IBD, IBS and antibiotic-associated diarrhea to accelerate clinical R&D.
o Apply for national Major New Drug Creation special grants and local R&D subsidies to cut R&D costs; commission professional CRO institutions to conduct clinical trials and shorten development cycles.
3. Manage Patents & Cooperation, Break Patent Barriers and Mitigate Infringement Risks
o Partner with domestic independent strain R&D suppliers to obtain licensing rights for high-activity strains via patent authorization and joint R&D, bypassing foreign patent monopolies.
o File patents covering strain improvement, formulation technology and expanded indications to build independent intellectual property systems and strengthen core competitiveness.
4. Standardize Compliant Production, Upgrade GMP Workshops and Refine Quality Control
o Renovate production workshops to meet pharmaceutical GMP standards, establishing a full-chain quality traceability system spanning raw materials to finished products for consistent product quality.
o Proactively communicate with drug regulatory authorities to clarify registration requirements in advance, shortening approval cycles and accelerating product commercialization.
The current market for Clostridium Butyricum and Bacillus Coagulans stands at a critical window of structural growth, technological upgrading, tightening supervision and scenario expansion, presenting both abundant opportunities and severe challenges for industry participants. For downstream B-end purchasers, core competitiveness hinges on mastering premium supply chains, precise strain selection, technological adaptation upgrades, robust compliance systems and differentiated product innovation.
As a foreign trade service provider with deep expertise in the two strains, we operate stable fermentation bases, independent strain R&D teams, full-chain quality inspection systems and complete international certification qualifications. We supply full-specification feed-grade, food-grade, health product-grade and pharmaceutical-grade strains, support customized strain, formula and formulation R&D, and assist clients with international certification, compliance audits and clinical evidence accumulation.
We look forward to deepening cooperation with you to seize global market opportunities, resolve industry pain points, develop highly competitive products and achieve mutually beneficial win-win results.
+86-13120989737 
info@hisiaddi.com 
English
